With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.
Drew Gazetos, PharmD
Advertisement
Articles by Drew Gazetos, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
2
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
3
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
4
FDA Approves First Drug for Pediatrics With Irritable Bowel Syndrome With Constipation
5
